CRISPR is a biotechnology company focused on developing a cure for diseases based on the famous gene editing technology CRISPR-Cas9. This is a biotechnology that targets any piece of DNA in a cell and edits it (removal and replacement).
Products being developed by CRISPR Therapeutics:
Blood diseases: for hemophilia and sickle cell disease, the company is currently in the human trial phase (followed by market) of fetal gene-editing tactics to increase the amount of red blood cells are produced.
Cancer treatment: the company currently has 3 different products with the principle of CAR-T cells, which stands for T lymphocytes containing hybrid antigen receptor. T lymphocytes are responsible for attacking cells that show signs of cancer. By editing genes, CRISPR technology can improve the efficiency of T lymphocytes. Three products are currently in human trials.
With type 1 diabetes, in development, CRISPR's strategy is to transform stem cells into insulin-producing cells.
Some other diseases: glycogen storage disease, Duchenne muscular dystrophy, cystic fibrosis ... CRISPR is currently studying the possibility of modifying genes on the host to treat these diseases.